IO Biotech, Inc.

Equities

IOBT

US4497781090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
1.17 ^USD	-.--%		-1.68%	-37.77%

05-15	HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating	MT
05-14	IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

IO Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 11, 2022 at 04:38 pm

IO Biotech, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 18.5 million compared to USD 38.36 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to USD 228.29 a year ago. Diluted loss per share from continuing operations was USD 0.64 compared to USD 228.29 a year ago.
For the six months, net loss was USD 35.7 million compared to USD 42.11 million a year ago. Basic loss per share from continuing operations was USD 1.24 compared to USD 259.82 a year ago. Diluted loss per share from continuing operations was USD 1.24 compared to USD 259.82 a year ago.

Latest news about IO Biotech, Inc.

HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating	05-15	MT
IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	04-26	CI
IO Biotech Announces Marjan Shamsaei as Senior Vice President	04-15	CI
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103	04-09	CI
IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer	04-05	CI
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting	03-06	CI
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
IO Biotech Doses First Patient in Phase 2 Trial of Melanoma Treatment	12-21	MT
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	12-21	CI
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
IO Biotech Appoints Helen Collins, Md, to Its Board of Directors	11-13	CI
IO Biotech Completes Enrollment in Pivotal Phase 3 Trial in Advanced Melanoma	11-10	MT
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma	11-10	CI
IO Biotech Says Non-Small Cell Lung Cancer Therapy Showed Partial Response in More Than Half of Evaluable Patients	23-10-23	MT
IO Biotech, Inc. Announces Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology Congress	23-10-23	CI
Piper Sandler Starts IO Biotech at Overweight	23-09-28	MT
Transcript : IO Biotech, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 04:15 PM	23-09-12
IO Biotech Reports 'Encouraging' Data from Phase 2 Trial of IO102-IO103, Keytruda Combination to Treat Lung Cancer	23-09-12	MT
Morgan Stanley Adjusts Price Target on IO Biotech to $7 From $11, Maintains Overweight Rating	23-08-15	MT
IO Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors	23-08-11	CI
IO Biotech Launching $75 Million Private Stock Placement; Shares Rise	23-08-07	MT
IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investors	23-08-06	CI

Chart IO Biotech, Inc.

Duration

Period

More charts

Company Profile

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâs product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâs lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.17 USD

Average target price

9.75 USD

Spread / Average Target

+733.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IO BIOTECH, INC.	-37.77%	77.08M
MODERNA, INC.	+19.41%	45.51B
IQVIA HOLDINGS INC.	-8.62%	38.52B
LONZA GROUP AG	+38.65%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research